Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.
- Mass Screening/organization & administration/statistics & numerical data
- Mothers/statistics & numerical data
- Papillomavirus Vaccines/*administration & dosage/adverse effects
- Patient Acceptance of Health Care/*statistics & numerical data
- Uterine Cervical Neoplasms/prevention & control
- Vaccination/*statistics & numerical data